Navigation auf


Life Science Zurich Communication & Events

Halting a malformation of the heart

Researchers at ETH Zurich have now shown that a previously unknown protein plays a key role in a congenital malformation of the heart. Their findings point the way towards new treatment options.

Congenital heart defects count as rare disease, but they have a serious impact on those afflicted. (Visualisations: Symbol image created using AI / Adobe Stock)

In brief

  • A protein called BBLN is highly elevated in the tissue of babies with a severe form of congenital heart defect - tetralogy of Fallot.
  • Researchers at ETH Zurich have been able to show how to change the biochemical signalling pathways involving this protein in order to stop the cardiac remodelling typical of tetralogy of Fallot.
  • Patients could one day benefit if it proves possible to find active substances based on the new findings.

ETH News